Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacology > Cancer Therapeutics > Flashcards

Cancer Therapeutics Flashcards

0
Q

Combination therapy for high-grade & intermediate Non-Hodgkin lymphomas (Burkitt lymphoma, lymphoblastic lymphoma, etc)

A

CHOP = Cyclophosphamide + Doxorubicin (Hydroxydaunorubicin) + Vincristine (Oncovin) + Prednisone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Combination therapy for Hodgkin lymphoma

A

MOPP = Mechlorethamine + Vincristine (Oncovin) + Procabazine + Prednisone

ABVD = Doxorubicin (Adriamycin) + Bleomycin + Vinblastine + Dacarbazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Combination therapy for newly-diagnosed pediatric ALL

A

Vincristine, a corticosteroid (either dexamethasone or prednisone), L-asparaginase, and anthracycline (either doxorubicin or daunorubicin)

**NB: children with ALL are treated according to risk groups, defined by both clinical and laboratory features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Combination therapy for node-positive breast cancers

A

FEC (CEF) = Fluorouracil + Epirubicin + Cyclophosphamide

FAC (CAF) = Fluorouracil + Doxorubicin (Adriamycin) + Cyclophosphamide

CMF = Cyclophosphamide + Methotrexate + Fluorouracil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Combination therapy for brain cancers (anaplastic astrocytoma, glioblastoma, anaplastic oligodendroglioma)

A

PCV = Procarbazine + Lomustine (CCNU) + Vincristine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Combination therapy for germ cell cancers (ovarian germ cell cancer, testicular cancer)

A

PEB = Cisplatin (Platinum) + Etoposide + Bleomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Combination therapy for MM

A

MP = Melphalan + Prednisone
(Old…now M + Bortezomib is standard 1st line therapy).

Avoid melphalan/other alkylation agents if pt is candidate for subsequent stem cell transplantation

VAD = Vincristine + Adriamycin + Dexamethasone

Lenalidomide + dexamethasone = effective 1st line therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Combination therapy for metastatic colorectal carcinoma

A

FOLFOX = Fluorouracil + Leucovorin + Oxaliplatin

FOLFIRI = Folate + FU + Irinotecan

FOLFOX/FOLFIRI + Bevacizumab is now a standard combo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mechlorethamine

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cyclophosphamide

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Melphalan

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Thiotepa

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dacarbazine

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Procarbazine

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Temozolomide

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Carmustine

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lomustine

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Busulfan

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Cisplatin

A

Platinum compound asso w/severe emesis, nephrotoxicity, irreversible neurotoxicity, and hearing loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Carboplatin

A

Platinum compound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Oxaliplatin

A

Platinum compound asso w/peripheral sensory neuropathy, which tends to be reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Granisetron

A

Anti-emetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Ordansetron

A

Anti-emetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Daunorubicin

A

Anthracycline/Anti-neoplastic ABx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Doxorubicin/Adriamycin
Anthracycline/Anti-neoplastic ABx
26
Epirubicin
Anthracycline/Anti-neoplastic ABx
27
Idarubicin
Anthracycline/Anti-neoplastic ABx
28
Mitomycin
Anti-neoplastic ABx
29
Dactinomycin
Anti-neoplastic ABx
30
Bleomycin
Anti-neoplastic ABx
31
Vinblastine
Antimicrotubule agent; inhibits microtubule assembly/destabilizes microtubules. BM suppression = D-L toxicity. Shortest half-life, fastest clearance rate of the vinca alkaloids
32
Vincristine
Antimicrotubule agent; inhibits microtubule assembly/destabilizes microtubules. Crosses BBB. Neurotoxicity = D-L toxicity
33
Vinorelbine
Antimicrotubule agent; inhibits microtubule assembly/destabilizes microtubules. BM suppression = D-L toxicity
34
Paclitaxel
Antimicrotubule agent; inhibits microtubule disassembly/stabilizes microtubules. D-L toxicity = neutropenia
35
Docetaxel
Antimicrotubule agent; inhibits microtubule disassembly/stabilizes microtubules. D-L toxicity = neutropenia
36
Premeds for taxanes (paclitaxel and docetaxel)
Glucocorticoids (dexamethasone) and/or antihistamines (diphenhydramine)
37
Methotrexate
Folate antagonist. Single agent curative for choriocarcinoma
38
Pemetrexed
Folate antagonist
39
Fluorouracil
Pyrimidine antagonist
40
Capecitabine
Pyrimidine antagonist
41
Cytarabine
Pyrimidine antagonist
42
Gemcitabine
Pyrimidine antagonist
43
Decitabine
Pyrimidine antagonist
44
Mercaptopurine
Purine antagonist
45
Fludarabine
Purine antagonist
46
Cladribine
Purine antagonist
47
Thioguanine
Purine antagonist
48
Nelarabine
Purine antagonist
49
Dasatinib
Kinase inhibitor. Inhibits imatinib-resistant BCR/ABL and other kinases. Approved for imatinib-resistant CML
50
Erlotinib
Kinase inhibitor; reversibly competes for the binding of ATP to the tyrosine kinase domain of the EGFR tyrosine kinase (like gefitinib). For treatment of locally advanced or metastatic NSCLC refractive to chemotherapy. Most common ADEs are diarrhea and rash.
51
Gefitinib
Kinase inhibitor; targets EGFR kinase. Originally approved for the treatment of NSCLC refractive to chemotherapy. Indicated only for cancer pts who currently or previously have benefited from treatment.
52
Imatinib/Gleevec
Kinase inhibitor; selective inhibitor of BCR/ABL, c-kit, and PDGFR tyrosine kinases. Used to treat CML, GIST, and DFSP (dermatofibrosarcoma protuberans). Well tolerated, side effects generally limited to rash, periorbital edema, fluid retention, diarrhea, and myalgia
53
Lapatinib/Tykerb
Kinase inhibitor; dual inhibitor of HER2 and EGFR protein kinases. For the treatment of patients w/advanced or metastatic breast cancer whose tumors overexpress HER2.
54
Nilotinib
Kinase inhibitor. Inhibits imatinib-resistant BCR/ABL. Approved for imatinib-resistnat CML.
55
Sorafenib
Kinase inhibitor. Dual inhibitor of the protein kinase Raf and of VEGFR protein-tyrosine kinases. For use in the treatment of advanced renal cell carcinoma and for unresectable HCC.
56
Bicalutamide
Anti-androgen
57
Flutamide
Anti-androgen
58
Aminoglutethimide
Aromatase inhibitor
59
Anastrozole
Aromatase inhibitor
60
Letrozole
Aromatase inhibitor
61
Tamoxifen
SERM/partial agonist of ER/impairs transcription of estrogen-dependent genes by binding to estrogen response elements (EREs) Highly effective for postmenopausal women with ER+ breast cancer; also effective in preventing breast cancer in high-risk patients by 50% A 10x lower affinity than estradiol for the ER
62
Toremifene
SERM
63
Goserelin & Leuprolide
GnRH Agonists. Targets testosterone-dependent prostate cancer growth. ADEs = initial symptomatic flair, hot flashes, impotence, gynecomastia
64
Trastuzumab (Herceptin)
For use as single agent or in combination with paclitaxel for metastatic HER2+ BC. Recently approved for stomach cancer in combination with chemotherapy in pts with metastatic gastric/gastroesophageal junction adenocarcinoma that expresses HER2.
65
Cardiomyopathy
Most serious ADE of trastuzumab
66
ADCC
Mechanism of action of trastuzumab
67
Cetuximab
Used in combination with irinotecan for EGFR+ metastatic colorectal cancer Binding prevents Kras activation
68
Rituximab
Used for the treatment of CD20+ B cell NHL (and CLL)
69
ADCC, complement
Mechanisms of action of rituximab
70
Bevacizumab (Avastatin)
Binds VEGF; used in combination with 5-FU for the treatment of metastatic colorectal cancer. Appears to "normalize" tumor vasculature, which improves drug deliver to the tumor and may improve RT.

Pharmacology (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions